CN111556869A - 作为csf-1r抑制剂的杂环化合物及其应用 - Google Patents

作为csf-1r抑制剂的杂环化合物及其应用 Download PDF

Info

Publication number
CN111556869A
CN111556869A CN201980007356.9A CN201980007356A CN111556869A CN 111556869 A CN111556869 A CN 111556869A CN 201980007356 A CN201980007356 A CN 201980007356A CN 111556869 A CN111556869 A CN 111556869A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
isomer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980007356.9A
Other languages
English (en)
Inventor
钱文远
杨纯道
徐光海
李婕
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN111556869A publication Critical patent/CN111556869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

本发明涉及一类异吲哚啉酮衍生物，及其在制备治疗与新型集落刺激因子‑1受体(colony stimulating factor 1 receptor，CSF‑1R)抑制剂相关疾病的药物中的应用。具体涉及式(Ⅰ)所示化合物及其药学上可接受的盐或其立体异构体。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980007356.9A 2018-01-03 2019-01-03 作为csf-1r抑制剂的杂环化合物及其应用 Pending CN111556869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810005326 2018-01-03
CN2018100053261 2018-01-03
PCT/CN2019/070228 WO2019134662A1 (zh) 2018-01-03 2019-01-03 作为csf-1r抑制剂的杂环化合物及其应用

Publications (1)

Publication Number Publication Date
CN111556869A true CN111556869A (zh) 2020-08-18

Family

ID=67144334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980007356.9A Pending CN111556869A (zh) 2018-01-03 2019-01-03 作为csf-1r抑制剂的杂环化合物及其应用

Country Status (5)

Country Link
US (1) US11384065B2 (zh)
EP (1) EP3738961B1 (zh)
JP (1) JP2021509897A (zh)
CN (1) CN111556869A (zh)
WO (1) WO2019134662A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023125812A1 (zh) * 2021-12-31 2023-07-06 上海海雁医药科技有限公司 取代的嘧啶酮衍生物、其药物组合物及医药上的用途
WO2023241608A1 (en) * 2022-06-15 2023-12-21 Myrobalan Therapeutics Nanjing Co. Ltd Csf-1r inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633710A1 (en) * 2003-06-02 2006-03-15 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
US20100076051A1 (en) * 2003-06-02 2010-03-25 Abbott Laboratories Isoindolinone kinase inhibitors
US20110275630A1 (en) * 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
GB201211310D0 (en) * 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
KR101846475B1 (ko) * 2015-04-27 2018-04-09 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
CA3001799A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2019134661A1 (zh) 2018-01-03 2019-07-11 南京明德新药研发股份有限公司 异吲哚啉酮及其衍生物作为csf-1r抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633710A1 (en) * 2003-06-02 2006-03-15 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
US20100076051A1 (en) * 2003-06-02 2010-03-25 Abbott Laboratories Isoindolinone kinase inhibitors
US20110275630A1 (en) * 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물

Also Published As

Publication number Publication date
US20210107894A1 (en) 2021-04-15
EP3738961B1 (en) 2022-08-31
US11384065B2 (en) 2022-07-12
JP2021509897A (ja) 2021-04-08
WO2019134662A1 (zh) 2019-07-11
EP3738961A4 (en) 2021-06-30
EP3738961A1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
CN110944989B (zh) 作为egfr激酶抑制剂的芳基磷氧化合物
KR102089234B1 (ko) Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
TWI690531B (zh) Ｊａｋ抑制劑
CN107531711B (zh) Janus激酶抑制剂
CN111372925B (zh) 作为c-MET/AXL抑制剂的尿嘧啶类化合物
KR102513448B1 (ko) Cdk4/6 억제제
CN111542520B (zh) 作为a2a受体抑制剂的并环类衍生物
CN111372937B (zh) 噻吩并二氮杂卓衍生物及其应用
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN109661395B (zh) Pde4抑制剂
CN110461855B (zh) 氮杂环丁烷衍生物
CN110023286B (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
CN109661391B (zh) S1p1激动剂及其应用
CN111148515A (zh) 2,6-二氧杂螺[4,5]癸烷类衍生物、其制备方法及其在医药上的应用
CN111247161B (zh) 用作iap抑制剂的smac模拟物及其用途
CN111479808B (zh) 嘧啶磺酰胺类衍生物、其制备方法及其在医药上的应用
CN109071469B (zh) 三环类化合物及其应用
CN110741003B (zh) 作为gls1抑制剂的化合物
WO2017202376A1 (zh) 磺酰胺衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034314

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200818

WD01 Invention patent application deemed withdrawn after publication